

1 **Protection conferred by Delta and BA.1/BA.2 infection against BA.4/BA.5 infection and**  
2 **hospitalization: A Retrospective Cohort Study**

3 Nicole E Winchester, BS<sup>1</sup>, Nabin K. Shrestha, MD<sup>2</sup>, Priscilla Kim, BA, MS<sup>1</sup>, Larisa G.  
4 Tereshchenko, MD, PhD<sup>3</sup>, Michael B Rothberg, MD, MPH<sup>3</sup>

5 <sup>1</sup>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland,  
6 Ohio, USA

7 <sup>2</sup>Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USA

8 <sup>3</sup>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA

9 <sup>4</sup>Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA

10

11 **Author Contributions and Conflicts of Interest:** We have no conflicts of interest to disclose. All  
12 authors have seen and approved the manuscript, and have contributed significantly to the work.  
13 The statistical analyses were conducted by NEW and LGT. No funding was received to assist  
14 with the preparation of this manuscript

15

16 **Abstract**

17 **Background:** SARS-CoV-2 immunity has declined with subsequent waves and accrual of viral  
18 mutations. In vitro studies raise concern for immune escape by BA.4/BA.5, and a study in Qatar  
19 showed moderate protection, but these findings have yet to be reproduced.

20 **Methods:** This retrospective cohort study included individuals tested for COVID-19 by PCR  
21 during Delta or BA.1/BA.2 and retested during BA.4/BA.5. The preventable fraction (PF) was  
22 calculated as ratio of the infection/hospitalization rate for initially positive patients divided by  
23 infection/hospitalization rate for initially negative patients, stratified by age, and adjusted for  
24 age, gender, comorbidities, and vaccination using logistic regression.

25 **Results:** 20,987 patients met inclusion criteria. Prior Delta infection provided no protection  
26 against BA.4/BA.5 infection (Adjusted PF: 11.9% (95% confidence interval [CI], 0.8-21.8);  
27  $p=0.036$ ) and minimal protection against hospitalization (Adjusted PF: 10.7% (95%CI, 4.9-21.7);  
28  $p=0.003$ ). In adjusted models, prior BA.1/BA.2 infection provided 45.9% (95%CI, 36.2-54.1) ( $p$   
29  $<0.001$ ) protection against BA.4/BA.5 reinfection and 18.8% (95% CI, 10.3-28.3) ( $p<0.0001$ )  
30 protection against hospitalization. Up-to-date vaccination provided modest protection against  
31 reinfection with BA.4/BA.5 and hospitalization.

32 **Conclusions:** Prior infection with BA.1/BA.2 and up-to-date vaccination provided modest  
33 protection against infection with BA.4/BA.5 and hospitalization, while prior Delta infection  
34 provided minimal protection against hospitalization, and no infection protection.

35

36 **Introduction**

37 Since the emergence of SARS-CoV-2 in 2019, multiple new strains have emerged, challenging  
38 the protection afforded by natural immunity, vaccination, and neutralizing antibody  
39 treatments. In the United States, these variants have included B.1.1.7 (Alpha), B.1.351 (Beta),  
40 B.1.1.28.1 (Gamma) and B.1.617.2 (Delta) [1], and most recently Omicron [1]. Prior to the  
41 emergence of Omicron, previous infection appeared to provide 80-90% protection against  
42 reinfection [2-9]. However, infection with pre-Omicron variants only provided 18-69%  
43 protection against reinfection with Omicron [10-11]. Since then, additional spike protein  
44 mutations have accrued, enabling progressive immune escape by new Omicron sub lineages  
45 [12-14].

46 By June 25<sup>th</sup>, two new Omicron subvariants, BA.4 and BA.5, became dominant in the United  
47 States [1]. *In vitro* studies raise concern that their additional spike protein mutations may  
48 enable immune evasion and repeat Omicron infections. Antibodies generated against the spike  
49 protein by BA.1 infection are evaded by BA.4/BA.5 [12], and neutralizing antibody titers  
50 following triple vaccination [13] or previous infection with BA.1 or BA.2 are substantially lower  
51 [13]. However, these studies have been limited to *in vitro* analysis of humoral immunity. A  
52 recent study in Qatar showed that infection with pre-Omicron variants was 28% effective at  
53 protecting against BA.4/BA.5 infection, while infection with early Omicron variants was 76%  
54 effective [15]. However, these findings have yet to be reproduced or evaluated in other  
55 populations, including the US, where patients are substantially older [15]. Moreover, this study  
56 did not assess the impact of prior infection or vaccination on hospitalization. Clinical data are

57 needed to define such protection in order to guide quarantine and isolation guidelines and  
58 future vaccine development.

59 As the pandemic has progressed, the public health priority has shifted from preventing all  
60 infections to reducing disease spread and disease severity, especially hospital admissions. We  
61 therefore designed our study to address two specific aims: 1) to determine the degree to which  
62 infection with Delta or Omicron subvariants BA.1/BA.2 and up-to-date vaccination protects  
63 against reinfection with BA.4/BA.5 and 2) to determine the preventable fraction of BA.4/BA.5  
64 hospitalizations attributable to prior infection with Delta or BA.1/BA.2 and up-to-date  
65 vaccination.

## 66 **Methods**

### 67 *Study Design*

68 We conducted a retrospective cohort study of patients within the Cleveland Clinic health  
69 system.

### 70 *Study Populations and SARS-CoV-2 Exposures*

71 The study population included individuals aged 18 years or older tested for COVID-19 via  
72 polymerase chain reaction (PCR) between July 1, 2021 and August 18, 2022. To assess the  
73 protection afforded by Delta and early Omicron (BA.1/BA.2) infection against BA.4/BA.5, the  
74 data were divided into two cohorts according to the CDC reported variant proportions. Patients  
75 tested between July 1, 2021 and December 25, 2021 were included in the Delta cohort. Patients  
76 tested between December 26, 2021 and June 24, 2021 were included in the BA.1/BA.2 cohort.

77 Only patients tested during Delta and/or BA.1/BA.2 and then retested during the period of  
78 BA.4/BA.5 predominance (June 25, 2022 to August 18, 2022) were included. Patients with a  
79 positive COVID test before July 1, 2021 or during both the Delta and BA.1/BA.2 waves were  
80 excluded. In addition, because the CDC defines reinfection as occurring  $\geq 90$  days after initial  
81 testing, patients with a positive test within 90 days of BA.4/BA.5 testing were also excluded.  
82 Patients with PCR testing during Delta and BA.1/BA.2 were included in both analyses if they  
83 only tested positive during one wave, or neither. The reasons for PCR testing included  
84 symptoms consistent with  
85 COVID-19, hospital admission for any indication, pre-procedural screening, and travel  
86 clearance.

87  
88 COVID vaccination status at the time of BA.4/BA.5 predominance was confirmed by review of  
89 the EMR. Patients were classified as up-to-date if they had completed a two-dose series  
90 (Moderna or Pfizer) or a single dose vaccine (Johnson & Johnson's Janssen or Astra Zeneca  
91 vaccine) and then received an additional vaccine dose within six months prior to June 25, 2022.

#### 92 *Data Collection*

93 Data were extracted from the electronic medical record. Variables collected included age, sex,  
94 BMI, ICD-9 codes for hypertension, diabetes mellitus, chronic kidney disease, heart failure, and  
95 stroke as well as COVID vaccine dose type and date(s), COVID PCR test date(s) and indications,  
96 hospitalization, ICU admission, and mechanical ventilation.

#### 97 *Statistical Analysis*

98 Infection rates were calculated as the number of positive tests divided by the total number of  
99 subjects retested. For aim 1, the fraction of BA.4/BA.5 infections that could have been  
100 prevented (preventable fraction (PF)) by prior infection with Delta or BA.1/BA.2 was calculated  
101 as 1 minus the ratio of the infection rate for initially positive patients divided by the infection  
102 rate for initially negative patients.

$$PF_{reinfection} = 1 - Risk\ Ratio$$
$$= 1 - \frac{BA.4/BA.5\ infection\ rate\ amongst\ previously\ infected}{BA.4/BA.5\ infection\ rate\ amongst\ previously\ uninfected}$$

103 To assess for differences in protection by age, we stratified the preventable fraction by age (18-  
104 64 years, 65 years and up). Lastly, the adjusted PF of infection was calculated by logistic  
105 regression, comparing the odds of having versus not having prior SARS-CoV-2 infection among  
106 patients with BA.4/BA.5 infection as:

$$107 \text{ Adjusted } PF_{reinfection} = 100 \times (1 - \text{Adjusted Odds Ratio}_{reinfection})$$

108

109 Logistic regression models were adjusted for age, sex, body mass index (BMI), and  
110 comorbidities (hypertension, diabetes mellitus, chronic kidney disease, heart failure, and  
111 stroke). Each model included an indicator variable for prior infection during Delta or BA.1/BA.2  
112 and an indicator variable for up-to-date vaccination.

113 For the second aim, the adjusted PF was calculated for hospitalization. The fraction of  
114 BA.4/BA.5 hospital admissions that could have been prevented (PF) by prior infection with  
115 Delta or BA.1/BA.2 was calculated as:

$$116 \text{ Adjusted } PF_{hospitalization} = 100 \times (1 - \text{Adjusted Odds Ratio}_{hospitalization})$$

117  
118 Logistic regression models were adjusted for age, sex, BMI, comorbidities (hypertension,  
119 diabetes mellitus, chronic kidney disease, heart failure, and stroke), and included an indicator  
120 variable for prior infection during Delta or BA.1/BA.2 and up-to-date vaccination.  
121 Analyses were conducted using R v.4.2.1 (R Core Team, Vienna) and STATA/MP 17.0 (StataCorp,  
122 College Station, TX). To adjust for testing of 10 hypotheses, p-value < 0.005 was considered to  
123 be statistically significant. The Cleveland Clinic Institutional Review Board approved this work.

## 124 **Results**

125 Between July 1, 2021 and August 18, 2022, 20,987 individuals met study inclusion criteria  
126 (average age, 58.5 ± 19.2 years; 57.4% female). Characteristics of patients who received a PCR  
127 test during the period of Delta, BA.1/BA.2, and BA.4/BA.5 predominance are shown in Table 1.  
128 During the Delta wave, 15,658 patients were tested for SARS-CoV-2 by PCR, of whom 15.2%  
129 tested positive. During the period of Omicron subvariants BA.1/BA.2 predominance, 10,545  
130 patients were tested for SARS-CoV-2 by PCR, of whom 17.9% tested positive. Overall, 17.0% of  
131 these individuals retested positive during BA.4/BA.5.

## 132 ***Protection against reinfection with Omicron subvariants BA.4/BA.5 by prior SARS-CoV-2*** 133 ***infection***

134 In unadjusted analyses, previous infection with BA.1/BA.2 provided modest protection against  
135 reinfection during the period of BA.4/BA.5 predominance with a PF of 38.0% (95% CI, 29.9-  
136 43.3%). However, prior Delta infections did not provide any protection against BA.4/BA.5

137 reinfection in unadjusted analyses. PF of BA.4/BA.5 infections by prior Delta infection was 5.5%  
138 (-2.8 to 13.2%).

139 Protection against reinfection stratified by age is shown in Table 2. Older adults ( $\geq 65$  years)  
140 infected during BA.1/BA.2 appeared to derive greater protection against reinfection than did  
141 younger adults ( $< 65$ ).

142 After adjusting for age, gender, BMI, comorbidities (HTN, DM, CKD, CHF, stroke), and up-to-  
143 date vaccination status, prior infection with BA.1/BA.2 still provided modest protection against  
144 BA.4/BA.5 reinfection. Prior BA.1/BA.2 infection conferred 45.9% (95% CI, 36.2-54.1)( $p < 0.0001$ )  
145 protection against reinfection with BA.4/BA.5. After adjustment, prior Delta infection provided  
146 no protection against BA.4/BA.5, 11.9% (95%CI, 0.8-21.8);  $p = 0.036$ . In the Delta model, up-to-  
147 date vaccination status provided significant protection against BA.4/BA.5, with a PF of 22.7%  
148 (95%CI, 14.8-29.8);  $p < 0.0001$ . The efficacy of up-to-date vaccination against BA.4/BA.5 in the  
149 BA.1/BA.2 model was 29.8% (95%CI, 20.5-38.1);  $p < 0.0001$ .

### 150 ***Prevention of hospitalization***

151 In the unadjusted analysis, previous infection with SARS-CoV-2 during the BA.1/BA.2 wave  
152 offered 44.6% (95% CI, 31.7-55.7) protection against hospitalization during the BA.4/BA.5 wave.  
153 Delta infections did not confer significant protection against hospitalization during BA.4/BA.5.  
154 However, after adjusting for age, gender, comorbidities, and vaccination status, prior Delta  
155 infection was effective at preventing 10.7% (95%CI, 4.9-21.7)( $p = 0.003$ ) of BA.4/BA.5  
156 hospitalizations, while BA.1/BA.2 infection prevented 18.8% (95%CI, 10.3-28.3);  $p < 0.0001$ .  
157 Efficacy of up-to-date vaccination in preventing hospitalization, after adjustment, was 20.0%

158 (95%CI, 13.9-25.7)( $p < 0.0001$ ) in the Delta model, and 22.9% (95%CI, 15.5-29.6)( $p < 0.0001$ ) in the  
159 BA.1/BA.2 model.

## 160 **Discussion**

161 In this retrospective cohort study of 20,987 individuals tested for SARS-CoV-2, previous Delta  
162 infection provided no protection against reinfection with Omicron subvariants BA.4/BA.5 and  
163 minimal protection against hospitalization. However, prior infection with earlier Omicron  
164 subvariants BA.1/BA.2 offered significant, albeit modest, protection against both reinfection  
165 and hospitalization. Up-to-date vaccination provided modest protection against hospitalization  
166 for both patients included in the Delta and BA.1/BA.2 analyses. Unexpectedly, we found that  
167 protection against reinfection was greater for older adults than for those under the age of 65  
168 years.

169 Our study demonstrates that infection with pre-Omicron variant Delta offers no significant  
170 protection against BA.4/BA.5 infection. This is consistent with *in vitro* studies showing complete  
171 immune evasion of BA.4/BA.5 by neutralizing antibodies induced by prior infections or  
172 vaccination. Clinical studies have shown a progressive decline in protection conferred by prior  
173 SARS-CoV-2 infection against newer variants. While SARS-CoV-2 infection provided 80-90%  
174 protection against reinfection with pre-Omicron variants [2-9], studies of the initial Omicron  
175 variant found that past infection, at least with Delta, offered some protection, but not at the  
176 levels seen with earlier variants [10,16]. A recent study in Qatar found that pre-Omicron  
177 infections were 27.7% (95% CI, 19.3 to 35.2) effective at preventing BA.4/BA.5 infections [15]. It  
178 is important to note that they matched cases and controls by the week of their COVID test,



179 which could better adjust for potential waning in natural immunity over time. However, we  
180 have previously shown that waning does not occur for at least 12 months [4,6]. Additionally,  
181 their study included individuals who received antigen testing and adjusted for testing  
182 indication. Their population was generally young and asymptomatic, and they therefore did not  
183 report on hospitalizations. Our cohort included an older, less healthy population, who received  
184 PCR testing in a healthcare setting rather than home antigen testing. Our cohort may therefore  
185 represent a population at higher risk of SARS-CoV-2 reinfection or adverse outcomes. Together,  
186 their findings and ours highlight a dramatic decline in the efficacy of natural immunity against  
187 newer SARS-CoV-2 variants, which may be most profound for our vulnerable populations.

188 Surprisingly, we found that following infection with BA.1/BA.2, older adults derived greater  
189 protection against BA.4/BA.5 than did younger adults. Prior studies have shown that natural  
190 immunity against COVID declines with advancing age. These unexpected findings, also seen  
191 with BA.1 [10], may be explained by differences in social behavior. It is plausible that following  
192 infection with COVID, older adults perceive their vulnerability and take greater precautions to  
193 avoid reinfection. Conversely, younger adults may feel they are protected against reinfection  
194 and no longer worry about catching it. Therefore they take fewer precautions, putting them at  
195 higher risk of exposure and infection. However, no differences were seen between younger and  
196 older adults with prior Delta infections. This suggests that the results were not completely a  
197 behavioral artifact. One explanation is that infection is dose dependent. Behaviors of older  
198 patients may have reduced the size of the inoculum and because the patients infected with  
199 BA.1/BA.2 had some immunity, they avoided infection, whereas older patients who had been

200 infected with Delta were susceptible even to a very small exposure. Alternatively, the impact of  
201 infection on behavior may have been short-lived.

202 Prior infection with BA.1/BA.2, and to a minimal degree, Delta, also offered significant  
203 protection against hospitalization. Rates of ICU admission and mechanical ventilation were  
204 remarkably low during BA.4/BA.5, at only 4.0 and 0.9%, respectively, making it impossible to  
205 assess the impact of prior infection on these more serious outcomes.

206 Lastly, these findings are a sobering reminder of the challenges in preventing the spread of  
207 COVID-19, and the need for ongoing vaccine development. Our findings suggest that natural  
208 immunity is insufficient to prevent reinfections with immunologically different variants. While  
209 in vitro studies suggested that vaccination may be ineffective against BA.4/BA.5 [17] , we found  
210 that up-to-date vaccination was modestly effective at preventing BA.4/BA.5 reinfection and  
211 hospitalization, even for patients without prior exposure to Omicron. These findings provide  
212 some reassurance and emphasize the importance of recent vaccination. Ongoing development  
213 of variant specific vaccines is needed to further improve their protective effect.

214 The strengths of this study include its large sample size, validity of PCR-confirmed SARS-CoV-2  
215 infection, and adjustment for vaccine status, age, and common comorbidities. Inclusion of  
216 these demographic and clinical characteristics allowed us to explore the separate roles of  
217 natural immunity and vaccination in preventing SARS-CoV-2 reinfections, as well as their  
218 interactions.

219 While we were able to adjust for certain demographic variables and comorbidities, this study  
220 has several important limitations. Due to the rapid uptake of home antigen testing following

221 the Delta wave, there may have been unmeasured differences between patients who  
222 presented for testing in the clinical setting versus testing at home. Additionally, greater time  
223 elapsed between Delta infections and BA.4/BA.5 exposure, than for BA.1/BA.2 infections.  
224 Several studies have shown that natural immunity persists for at least one year before waning  
225 [4,6]. However, our study alone cannot exclude the possibility that the lack of protection  
226 conferred by Delta infection is due to waning immunity. This study is also unable to account for  
227 differences in patient behavior involving avoidance of SARS-CoV-2 exposures. While age may  
228 account for some differences in behavior, we cannot further differentiate natural immunity  
229 from avoidance of exposures. Still, the extent to which we found minimal impact of previous  
230 infection remains concerning.

231 In conclusion, previous infection with Delta conferred no protection against reinfection with  
232 BA.4/BA.5 and minimal protection against hospitalization, regardless of vaccine status or age.  
233 BA.1/BA.2 infection offered limited protection against both. It seems unlikely that herd  
234 immunity will be possible. Future vaccines are necessary if more severe variants begin to  
235 circulate. Such vaccines will require rapid dissemination, prior to the emergence of new  
236 variants, in order to be effective as a public health intervention.

237

238

## References

239

- 240 1. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US  
241 Department of Health and Human Services, CDC; 2022, July 07. [https://covid.cdc.gov/covid-  
242 data-tracker](https://covid.cdc.gov/covid-<br/>242 data-tracker).
- 243 2. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who  
244 Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clin  
245 Infect Dis* 2021;73:1882-6.
- 246 3. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection  
247 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in  
248 2020: a population-level observational study. *Lancet* 2021;397:1204-12.
- 249 4. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of Severe Acute Respiratory  
250 Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A  
251 Retrospective Cohort Study. *Clin Infect Dis* 2022;75:e185-e90.
- 252 5. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2  
253 Infection in Health Care Workers. *N Engl J Med* 2021;384:533-40.
- 254 6. Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Necessity of Coronavirus  
255 Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19. *Clin Infect  
256 Dis* 2022;75:e662-e71.
- 257 7. Grant R, Charmet T, Schaeffer L, et al. Impact of SARS-CoV-2 Delta variant on incubation,  
258 transmission settings and vaccine effectiveness: Results from a nationwide case-control study in  
259 France. *Lancet Reg Health Eur* 2022;13:100278.
- 260 8. Leidi A, Koegler F, Dumont R, et al. Risk of Reinfection After Seroconversion to Severe  
261 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score  
262 Matched Cohort Study. *Clin Infect Dis* 2022;74:622-9.
- 263 9. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After  
264 Primary Infection in a Population in Lombardy, Italy. *JAMA Intern Med* 2021;181:1407-8.
- 265 10. Rothberg MB, Kim P, Shrestha NK, Kojima L, Tereshchenko LG. Protection Against the  
266 Omicron Variant Offered by Previous SARS-CoV-2 Infection: A Retrospective Cohort Study. *Clin  
267 Infect Dis* 2022.
- 268 11. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant  
269 from Previous SARS-CoV-2 Infection. *N Engl J Med* 2022;386:1288-90.
- 270 12. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by  
271 Omicron infection. *Nature* 2022;608:593-602.
- 272 13. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron  
273 Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med* 2022;387:86-8.
- 274 14. Callaway E. Heavily mutated Omicron variant puts scientists on alert. *Nature*  
275 2021;600:21.
- 276 15. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective Effect of Previous SARS-CoV-  
277 2 Infection against Omicron BA.4 and BA.5 Subvariants. *New England Journal of Medicine* 2022.
- 278 16. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant  
279 from Previous SARS-CoV-2 Infection. *New England Journal of Medicine* 2022;386:1288-90.
- 280 17. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by  
281 Omicron infection. *Nature* 2022.



283 **Table 1. Patient characteristics and unadjusted preventable fractions (PF) for prevention of**  
 284 **BA.4/BA.5 infection by prior SARS-CoV-2 infection status**

Characteristic	Delta		BA.1/BA.2		BA.4/BA.5	
	SARS-CoV-2(+)	SARS-CoV-2(-)	SARS-CoV-2(+)	SARS-CoV-2(-)	SARS-CoV-2(+)	SARS-CoV-2(-)
n	2,380	13,278	1,886	8,659	3,558	17,429
Age ± SD, y	52.3 ± 19.1	58.9 ± 19.1	55.7 ± 19.5	60.7 ± 18.4	56.4 ± 19.4	59.0 ± 19.1
Female, n (%)	1,378 (57.9)	7,785 (58.6)	1,075 (57.0)	4,781 (55.2)	2,093 (58.8)	9,956 (57.1)
HTN, n (%)	1,210 (50.8)	7,976 (60.1)	1,066 (56.5)	5,597 (64.6)	1,857 (52.2)	10,539 (60.5)
DM, n (%)	597 (25.1)	3,902 (29.4)	539 (28.6)	2,781 (32.1)	846 (23.8)	5,112 (29.3)
CHF, n (%)	361 (15.2)	2,885 (21.7)	373 (19.8)	2,183 (25.2)	505 (14.2)	3,799 (21.8)
CKD, n (%)	363 (15.3)	2,816 (21.2)	388 (20.6)	2,120 (24.5)	566 (15.9)	3,701 (21.2)
Stroke, n (%)	347 (14.6)	2,824 (21.3)	370 (20.6)	1,971 (22.8)	556 (15.6)	3,666 (21.0)
Overweight, n (%)	623 (26.2)	3,828 (28.8)	506 (26.8)	2,476 (28.6)	1,071 (30.1)	4,936 (28.3)
Obese, n (%)	1,198 (50.3)	5,453 (41.1)	838 (44.4)	3,647 (40.0)	1,505 (42.3)	7,306 (41.9)
BA.4/BA.5 +, n (%)	400 (16.8)	2,315 (17.4)	187 (9.9)	1,369 (15.8)	x	x
Up-to-date vaccination, n (%)	622 (26.1)	4,378 (33.0)	519 (27.5)	2,978 (34.4)	922 (25.9)	5,736 (32.9)
Unadjusted PF (95% CI), %	5.5 (-2.8-13.2)		38.0 (29.9-43.3)		x	
Adjusted PF (95% CI), %, (p-value)*	11.9(0.8-21.8) (p=0.036)		45.9(36.2-54.1) (p<0.0001)		x	

285 \*Adjusted for age, gender, and comorbidities. Both exposures (previous SARS-CoV-2 infection and vaccination)  
 286 were included in the model.

287

288

289

290 **Table 2. Protection against Reinfection with the Omicron subvariants BA.4/BA.5 by age group**

Wave	Age group (years)	BA.4/BA.5 reinfection cases, N		BA.4/BA.5 reinfection incidence proportion, %		Preventable fraction, %	Pairwise P-value
		Exposed	Unexposed	Exposed	Unexposed		
Delta	18-64	419	1,865	19.6%	19.4%	-1.1%	<0.001
	≥65	102	1,241	11.7%	17.0%	30.9%	Ref
BA.1/BA.2	18-64	192	1,035	12.4%	17.9%	30.9%	<0.001
	≥65	60	792	6.9%	15.6%	55.6%	Ref

291

292

293

294

295

296

297

298 **Table 3. BA.4/BA.5 infection outcomes by prior COVID Status and preventable fraction (PF) of**  
 299 **hospitalizations**

	Delta+ (n= 400)	Delta- (n= 2,315)	BA1BA2+ (n = 187)	BA1BA2- (n=1,369)
Hospitalization, n(%)	164 (41.1)	963 (41.6)	47 (25.1)	628 (45.9)
ICU admission, n(%)	11 (2.8)	93 (4.0)	5 (2.7)	62 (4.5)
Mechanical ventilation, n(%)	5 (1.3)	19 (0.8)	0	15 (1.1)
Hospitalization, Unadjusted PF (95% CI), %	1.3 (-9.9 – 12.0)		44.6 (31.7-55.7)	
Hospitalization, Adjusted PF (95%CI), % (p-value)*	10.7% (95%CI, 4.9-21.7) (p=0.003)		18.8% (95%CI, 10.3-28.3) (p<0.0001)	

300 \*Adjusted for age, gender, and comorbidities. Both exposures (previous SARS-CoV-2 infection and vaccination)  
 301 were included in the model.

302